Teva Lifts 2026 Outlook After 43% Surge in Key Brands and Plans Direct NYSE Listing
TEVA has more than doubled off its 52-week low of $14.99.
Summary
Teva's Q2 2026 results featured a 43% surge in key innovative brands to over $1 billion, leading to raised full-year guidance for AUSTEDO, AJOVY, and UZEDY. The company also announced a transition to a direct NYSE listing of ordinary shares, while a Fitch upgrade to investment grade and pipeline advances further support the Pivot to Growth strategy.
Key Events · Earnings and Guidance · TEVA
-
Key Innovative Brands Surge 43%
Combined Q2 revenue from AUSTEDO, AJOVY, and UZEDY topped $1 billion, a 43% year-over-year increase in local currency that drove the raised 2026 outlook to roughly $3.7 billion.
-
Raised 2026 Guidance
Teva lifted its 2026 revenue outlooks for AUSTEDO to $2.45–$2.6B, AJOVY to $850–$870M, and UZEDY to $270–$290M, while keeping total revenue guidance at $16.5–$16.85B and non-GAAP EPS at $1.91–$2.11.
-
ADS Program Replaced with Direct NYSE Listing
Effective September 14, 2026, Teva will terminate its ADS program and directly list ordinary shares on the NYSE, a move designed to broaden its shareholder base and support potential index inclusion.
-
Fitch Upgrades to Investment Grade
Fitch raised Teva's corporate credit rating to BBB-, citing a significantly improved balance sheet and successful execution of the Pivot to Growth strategy.
Analysis · TEVA · Life Sciences
A standout second quarter saw Teva's three innovative growth drivers—AUSTEDO, AJOVY, and UZEDY—deliver combined revenue of over $1 billion, a 43% year-over-year jump in local currency that prompted the company to raise its 2026 outlook for each. In a move to broaden its shareholder base and support index inclusion, Teva will replace its ADS program with a direct listing of ordinary shares on the NYSE. These developments reinforce the Pivot to Growth strategy, as the innovative portfolio reshapes the revenue mix and strengthens the financial profile—a shift validated by Fitch's upgrade to investment grade. The closing of the Emalex acquisition and the June 2026 submission of an NDA for ecopipam add a promising late-stage neuroscience asset, while progress on olanzapine LAI, duvakitug, and TEV-'408 underscores a deepening pipeline. Altogether, this report materially lifts the growth trajectory and de-risks the investment thesis.
At the time of this filing, TEVA was trading at $32.45 on NYSE in the Life Sciences sector, with a market capitalization of approximately $36.5B. The 52-week trading range was $14.99 to $37.35. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.